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Discussion
Dr Kenneth R. McCurry (Pittsburgh, Pa). I congratulate Dr
Kozower and his colleagues on their work. I think the impact of the
LAS on posttransplant outcomes as well as waiting list mortality
are critical issues that deserve a great deal of attention. This paper
is the first to address both sides of this equation in a comprehensive
fashion.
Dr Kozower and his colleagues have presented data from their
five institutions demonstrating a significant change in the distri-
bution of lung transplants by recipient diagnosis since implemen-
tation of the LAS system, with an increase in the percentage of
transplants being performed for idiopathic pulmonary fibrosis from
15% to 25% and a concomitant decrease in the percentage of
transplants being performed for chronic obstructive pulmonary
disease from 46% to 34%. As Dr Kozower has stated, these data
are certainly anticipated and indeed the intended effect of the LAS
system. They are also consistent with, although somewhat less
dramatic than, the initial 6-month analysis of United Network for
Organ Sharing data in October of 2005, where about 46% of the
transplants performed in the United States during the first 6 months
after initiation of the LAS were performed for restrictive lung
disease. At our own center in Pittsburgh, approximately 35% of
our patients received transplants for idiopathic pulmonary fibrosis
compared with about 18% previously. This distribution will obvi-
ously vary a little bit depending on the local referral practices and
the associated medical programs.
Also, interestingly, 2 weeks ago at the annual meeting of the
International Society for Heart and Lung Transplantation, the
Johns Hopkins Lung Transplant Program presented an abstract
evaluating global US 1-year survival under the new LAS system.
In their published abstract, they reported on 1486 lung transplants
that were performed in the United States from May 4, 2005, which
was the start date of the LAS system, through July 15, 2006. In the
group of patients with an LAS less than 44, they found a 1-year
survival of 73%, whereas the group with an LAS greater than or
equal to 44.4 had a significantly lower 1-year survival of approx-
imately 56%. In the five academic medical centers represented in
Dr Kozower’s paper, the mean LAS in the LAS era was 42 15.2,
yet they had a 1-year survival of 86.4%. These are certainly
excellent outcomes and the centers represented should be congrat-
ulated in that regard. This discrepancy does, however, raise the
question of whether these excellent outcomes can be universally
achieved in the undoubtedly sicker patient population that is and
will receive transplantation under the LAS system now and in the
future. As Dr Kozower has noted, however, the design of the LAS
system was not only to consider the medical urgency of potential
recipients, that is, those most likely to die without a transplant, but
also to consider net transplant benefit, taking into consideration
posttransplant survival as well as waiting list mortality. Thus, it is
imperative to evaluate the effect of the LAS system on waiting list
mortality, as you have done.
Intuitively, and certainly from personal experience, I do believe
that the waiting list mortality has declined under the LAS system.
Indeed, I believe that in 2005, when the LAS system was imple-
mented in the United States, there were about 350 deaths on the
waiting list that year compared with about 500 per year for the
previous 4 to 5 years. I do, however, have a question regarding the
methodology that you used to calculate waiting list mortality in
your paper. You describe estimating the denominator by determin-
ing the number of patients on the waiting list at 4 different time
points and then averaging these numbers to determine the average
number of patients waiting over the year, while the numerator was
the actual numbers of deaths while waiting. This method does not
take into account those patients who were removed from the
waiting list owing to progression of disease to a point of not being
transplantable. This event would also be a failure, I would think, of
whatever allocation system was in place at the time. Would it not
have been simpler and indeed more thorough to determine the fate
of each patient who was on the waiting list over the study period?
In this fashion, there would be four possible outcomes for each
patient—transplantation, death waiting, removed from the list ow-
ing to progression of disease, or continued waiting on the list—to
allow a more clear understanding of what happens to patients on
the lung transplantation waiting list.
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Dr Kozower. Thank you for your comments and for an excel-
lent first question. I agree with you that it would definitely be more
thorough to evaluate the outcome for every patient who was listed
for transplant. However, I am not sure it would be simpler. With
this retrospective cohort design, it was difficult for us to determine
how many patients were on the list at specific time points, and
some centers do not have records of patients listed for transplan-
tation. Given these limitations, our method of determining how
many patients were on the waiting lists seems reasonable.
Dr McCurry. I think it is going to be a critical issue going
forward.
My second question is, in your presentation you reported
that the rate of primary graft dysfunction as well as days of
mechanical ventilation and days in the ICU were significantly
greater in the LAS era than in the pre-LAS era, although only
ICU length of stay remained significant after adjustment for
diagnosis. Can you expand on the grade of primary graft dys-
function that you included in your paper? As you know, the
International Society for Heart ad Lung Transplantation now
has 4 different grades, 0 through 3, for primary graft dysfunc-
tion. Also, can you expand on why you think this rate was
increased in the LAS era? Did you look at other potential
recipient confounding factors, such as presence of pulmonary
hypertension, use of cardiopulmonary bypass, or transfusion
requirements? Did you look at donor demographics to assure
that they were equal between the two groups?
Dr Kozower. We defined primary graft dysfunction as grades
2 and 3, that is, an arterial oxygen tension/inspired oxygen fraction
less than 300 and a chest radiograph with the diffuse infiltrates.
This occurred within the first 3 days. As to why patients in the LAS
era had more primary graft dysfunction, I think for our series much
of that was shown to be due to the increase in patients requiring
transplantation for idiopathic pulmonary fibrosis.
The third part of your question is a good one. We did not look
at pulmonary artery pressures in both groups, but that is included
in the LAS score, which was higher in the LAS group. We did look
at the use of cardiopulmonary bypass and it was quite similar
between the two groups. In the pre-LAS era it was 34%, and for
the LAS group it was 37%, with a P value of .8.
Dr McCurry. Finally, what is your clinical impression as to
why ICU stay was prolonged? Were there more infectious com-
plications in the sicker patient population in the LAS, or did you
have more patients who were in the hospital awaiting transplan-
tation preoperatively? What was your clinical impression as to
why they stayed in the ICU longer?
Dr Kozower. My clinical impression is that these patients are
definitely sicker preoperatively. We have shown that there was a
significant increase in the LAS between the groups. You raise an
excellent point about infectious complications and in-house pa-
tients, but we did not collect those data.
Dr Thomas M. Egan (Chapel Hill, NC). I congratulate you
and your other institutions for outstanding results in sicker
patients.
I want to echo Dr McCurry’s comment about pulmonary hy-
pertension. Presumably, you did not change your donor acceptance
criteria from 1 year to the next, and so the incidence of primary
graft failure has to be recipient factors and not donor factors. That
would imply that you have to look at what the donor factors were.
Although you did not show a difference in diagnosis, my bet would
be that there is a difference in pulmonary pressures in those
patients, and pulmonary hypertension is a risk factor for primary
graft dysfunction.
Dr Kozower. I agree with you, Dr Egan. We did not examine
pulmonary artery pressure independently, but it is included in the
LAS algorithm, which was increased in the LAS group.
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